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Authors’ reply
We acknowledge the large hetero-
geneity in reported prevalence of 
rheumatic heart disease documented 
in our systematic review,1 and concur 
with Peter Murray and Caroline Shaw 
that the statistical combination of 
heterogeneous studies might have 
drawbacks. The exploration of potential 
sources of heterogeneity is therefore 
important and could provide more 
insight than the mechanistic calculation 
of the overall measure of eﬀ ect.2
As former US Secretary of State for 
Defence Donald Rumsfeld said, “There 
are known knowns. These are the things 
we know that we know. There are 
known unknowns. That is to say, there 
are things that we know we don’t know. 
But there are also unknown unknowns. 
There are things we don’t know we 
don’t know.”3 The potential sources of 
heterogeneity addressed by Murray 
and Shaw fall under the category of 
known unknowns, for which we tried 
to account by taking several measures. 
We assessed the methodological 
characteristics and summarised the 
clinical and echocardiographic criteria 
for case detection of all included studies 
in the online appendix, did sensitivity 
analyses, and transparently discussed 
the limitations of our findings. 
Additionally, we presented prediction 
intervals. These intervals represent the 
true uncertainty of a pooled estimate 
in the presence of unexplained or only 
partly explained heterogeneity, as 
is the case here. Beyond the known 
unknowns that we tried to address, 
we are confronted with residual 
confounders, unknown unknowns that 
might be uncovered only in subsequent 
studies.
Nevertheless, we believe that the 
main ﬁ ndings of our study are robust. 
We noted a progressive increase 
in the prevalence of rheumatic 
heart disease with advancing age 
of children, modelling different 
prevalence patterns across age groups 
separately for each study, and pooling 
estimates within each age group 
only in a second step, while taking 
into account the uncertainty of our 
estimates. Our findings suggest the 
potential importance of cumulative 
exposure to streptococcal infections. 
We noted a prevalence of silent 
rheumatic heart disease that was 
several times higher than clinically 
manifest disease, as previously shown 
by Marijon and colleagues,4 among 
others. Finally, we noted a statistically 
signiﬁ cant association of prevalence 
and social inequality. The eradication 
of rheumatic heart disease in high-
income countries was mediated by 
socioeconomic change. It is a known 
known that the answer to rheumatic 
heart disease resides in a reduction of 
poverty and facilitated access to health 
care. 
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